Detailed Information on Publication Record

@proceedings{60353,
   author = {Ladungová, Adriana and Peschelová, Helena and Dostálová, Lenka and Lodhi, Yusuf and Gottumukkala, Narendra Varma and Mayer, Jiří and Šmída, Michal},
   booktitle = {The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood},
   keywords = {BCL-2 inhibitor; acute myeloid leukemia; MCL1 upregulation},
   language = {eng},
   title = {Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.},
   url = {https://ashpublications.org/blood/article/142/Supplement%201/5759/505860/Exploring-the-Mechanisms-of-Venetoclax-Resistance},
   year = {2023}
}

TY  - CONF
ID  - 60353
AU  - Ladungová, Adriana - Peschelová, Helena - Dostálová, Lenka - Lodhi, Yusuf - Gottumukkala, Narendra Varma - Mayer, Jiří - Šmída, Michal
PY  - 2023
TI  - Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.
KW  - BCL-2 inhibitor
KW  - acute myeloid leukemia
KW  - MCL1 upregulation
UR  - https://ashpublications.org/blood/article/142/Supplement%201/5759/505860/Exploring-the-Mechanisms-of-Venetoclax-Resistance
N2  - Combining Venetoclax, a selective BCL-2 inhibitor, with hypomethylating agents has revolutionized frontline acute myeloid leukemia (AML) treatment. Despite its success, the occurrence of resistance remains a significant concern, limiting the range of available treatment alternatives. Little is known about the mechanism by which the cells escape the treatment. Recent studies have observed MCL1 upregulation in AML cells to promote resistance, and the rationale to use an MCL1 inhibitor became attractive. Although MCL1 inhibitors work exceptionally well in vitro their clinical trials were unsuccessful due to their toxicity. Here, we aim to identify other genes responsible for acquiring resistance and tackle the problem through screening for clinically approved drugs to rapidly benefit the patients with our study.
ER  - 

LADUNGOVÁ, Adriana, Helena PESCHELOVÁ, Lenka DOSTÁLOVÁ, Yusuf LODHI, Narendra Varma GOTTUMUKKALA, Jiří MAYER and Michal ŠMÍDA. Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. In \textit{The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood}. 2023.